Scott Gottlieb FDA

Scott Gottlieb leaving FDA: possible reasons, impact on stem cell field, & more

Dr.-Scott-Gottlieb

Maybe the announcement that Commissioner Scott Gottlieb will be leaving the FDA soon shouldn’t have caught us all off-guard, but it did. Gottlieb isn’t a perfect Commissioner, but he brought a sensible, open approach to running the FDA that was very refreshing. Amongst all the top leadership in the Trump administration, Scott Gottlieb stood out …

Scott Gottlieb leaving FDA: possible reasons, impact on stem cell field, & more Read More »

Fat stem cells are drugs & more: FDA final guidances point to a new era

FDA-stem-cell-policy-flow-chart-e1510854295902

Are fat stem cells a drug? Today the FDA definitively indicated “yes” without leaving much of any room for exceptions on this question. This morning the FDA made a major announcement on stem cell policy regarding its current thinking on oversight of regenerative medicine and issued four guidances, including two each in final and in …

Fat stem cells are drugs & more: FDA final guidances point to a new era Read More »

Reading the tea leaves as new FDA commish Gottlieb blogs on regenerative medicine

Dr.-Scott-Gottlieb

New FDA Commissioner Dr. Scott Gottlieb, M.D., has in the past touched on stem cells and regenerative medicine therapies in speeches or written comments prior to starting his tenure at the agency. Now that he is Commissioner, he is poised to have direct impact on our field rather quickly and potentially with major changes in …

Reading the tea leaves as new FDA commish Gottlieb blogs on regenerative medicine Read More »

How Scott Gottlieb may transform the FDA’s approach to stem cells

Dr.-Scott-Gottlieb

The Trump FDA commissioner nominee Dr. Scott Gottlieb could dramatically alter how the agency regulates investigational stem cell therapies. How might such changes unfold? There are potential upsides and downsides to  the seismic shift that could be in the offing. Gottlieb has written in the past about his perception of FDA over-regulation of stem cells such …

How Scott Gottlieb may transform the FDA’s approach to stem cells Read More »